Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma Academic Article uri icon

Overview

MeSH Major

  • Active Transport, Cell Nucleus
  • Antineoplastic Agents
  • Hydrazines
  • Sarcoma
  • Soft Tissue Neoplasms
  • Triazoles

abstract

  • Selinexor was well tolerated at a 60-mg flat dose on a 3-weeks-on, 1-week-off schedule. There was no clinically meaningful impact of food on PKs. Preliminary evidence of anticancer activity in sarcoma was demonstrated.

publication date

  • September 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5321073

Digital Object Identifier (DOI)

  • 10.1200/JCO.2016.67.6346

PubMed ID

  • 27458288

Additional Document Info

start page

  • 3166

end page

  • 74

volume

  • 34

number

  • 26